OpenAI CEO Sam Altman Had A Wobble, Says 2023 ‘Has Been A Crazy Year’
As 2023 ends, Sam Altman, the most talked about personality in the tech arena, says, "It's been a crazy year.
Is The Santa Rally Over? What It Means For Stocks In 2024
Ryan Detrick of The Carson Group compared the pullback to an absence of Santa Claus rallies and subsequent losses in the years 2000 and 2008.
US Stocks Bounce; Chipmakers, Cruise Lines Lead, Dollar Falls: What’s Driving Markets Thursday?
On Thursday, Wall Street rebounded into positive territory, following a brief dip experienced on Wednesday. At midday trading New York time, all major stock indices were trading in the green as traders prepared for the final trading week of the year.
Amazon Analyst Names 4 Key Pillars Supporting Advertising Opportunity in 2024
Amazon.com Inc (AMZN) stock has gained 78% this year. Wedbush expects Amazon to generate $46.5B in ad revenue in 2023, and sees a path to $100B+ of AWS/FCF/Ad rev by 2026/2028.
Why Is Cruise Operator Carnival Stock Creating Waves Today?
Carnival Corp (NYSE: CCL) (NYSE: CUK) shares are trading higher by around 7% after it
Why Is Immunotherapy-Focused Hookipa Pharma Stock Soaring Today?
Gilead Sciences Inc (NASDAQ: GILD) announced on Thursday that it has purchased 15 million shares of HOOKIPA Pharma Inc (NASDAQ: HOOK) for approximately $21.25 million,
3 Bitcoin Plays That Outperformed AI-Fueled Nvidia In 2023
In 2023, Nvidia's stock rose 230%. However, 3 Bitcoin-related stocks - MARA, RIOT & MSTR - outperformed it with 550%, 388% and 295% returns respectively.
The World’s Top 3 Most Valuable Brands In 2023: Hint — It’s Not Microsoft, Walmart Or Tesla
TradingPedia looked at the biggest companies in leading markets, and came up with a list of the Top 500 most valuable brands.
ADNOC Plans To Increase Takeover Proposal For Germany’s Covestro: Report
Abu Dhabi National Oil Co. (ADNOC) reportedly plans to increase its preliminary takeover offer for Covestro AG (OTC: COVTY).
Autoimmune Disease Player Immunovant’s Investigational Drug For Immune System Disorder Shows Response Rates Of Over 50%
Immunovant Inc (NASDAQ: IMVT), on Thursday, released the results from the initial cohort of patients in an ongoing 24-week Phase 2 trial of batoclimab in